Protein expression of VEGF, IGF-1 and FGF in retro-ocular connective tissues and clinical correlation in Graves' ophthalmopathy;Expressão protéica de VEGF, IGF-1 e FGF no tecido conjuntivo retro-ocular e correlação clínica na oftalmopatia de Graves

Arquivos Brasileiros de Oftalmologia

Volumn 71, Issue 4, 2008, Pages 486-492

  Matos, Kimble ^a   Manso, Paulo Gois ^a   Marback, Eduardo ^a,b   Furlanetto, Reinaldo ^a   Alberti, Gustave Nosé ^c   Nosé, Vania ^a,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c TUFTS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Epidermal growth factor analysis; Fibroblast growth factors analysis; Graves' ophthalmopathy metabolism; Imunohistochemstry; Insulin like growth factor I analysis; Platelet derived growth factor alpha analysis; Proto oncogene proteins c sis analysis; Receptor, epidermal growth factor analysis; Receptor, erbB 2 analysis; Vascular endothelial growth factor A analysis

Indexed keywords

FIBROBLAST GROWTH FACTOR; SOMATOMEDIN C; VASCULOTROPIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BIOPSY; CASE CONTROL STUDY; CONNECTIVE TISSUE; ENDOCRINE OPHTHALMOPATHY; EXTRAOCULAR MUSCLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; STATISTICAL ANALYSIS; STRABISMUS;

ADIPOSE TISSUE; ADULT; BIOPSY; CASE-CONTROL STUDIES; CONNECTIVE TISSUE; DATA INTERPRETATION, STATISTICAL; FEMALE; FIBROBLAST GROWTH FACTORS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCULOMOTOR MUSCLES; STRABISMUS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 67649227024     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492008000400004     Document Type: Article

References (30)

1. Matos K, Nosé V, Manso PG, Ho RF, Marback E, Nakanami C, et al. Correlation Between Clinical and Histological Analyses in Retroocular Connective Tissues and Extraocular Muscles from Patients with Graves' Opthalmopathy. Endocr Pathol. 2000;11(2):185-94.
2. Heufelder AE. [Pathogenesis of Graves' ophthalmopathy]. Z Arztl Fortbild Qualitatssich. 1999;93(Suppl 1):35-9. Review. German.
3. Binoux M, Hossenlopp P, Lassacre C, Hardouin N. Production of insulin-like growth factors and their carrier by rat pituitary gland and brain explants in culture. FEBS Lett. 1981;124(2):178-84.
4. Baxter RC. The somatomedins: insulin-like growth factors. Adv Clin Chem. 1986;25:49115. Review.
5. Tramontano D, Cushing GW, Moses AC, Ingbar SH. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology. 1986;119(2):940-2.
6. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9-14. Erratum in: Clin Endocrinol (Oxf). 1997;47(5):632. Comment in: Clin Endocrinol (Oxf). 1997;47(1):15
7. Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44(1):203-4.
8. Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 1995;119(6):792-5. Review.
9. Skalka HW. The use of ultrasonography in the diagnosis of endocrine orbitopathy. Neuroophthalmology. 1980;1:109-16.
10. Prummel MF, Suttorp-Schulten MS, Wiersinga WM, Verbeek AM, Mourits MP, Koornneef L. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy. Ophthalmology. 1993;100(4):556-61. Comment in: Ophthalmology. 1993;100(10):1430-1.
11. Byrne SF, Gendron EK, Glaser JS, Feuer W, Atta H. Diameter of normal extraocular recti muscles with echography. Am J Ophthalmol. 1991;112(6):706-13.
12. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet. 1991;338(8758):25-8. Comment in: Lancet. 1991;338(8764):454-5.
13. Marcocci C, Vitti P, Cetani F, Catalano F, Concetti R, Pinchera A. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab. 1991; 72(1):209-13.
14. Hufnagel TJ, Hickey WF, Cobbs WH, Jakobiec FA, Iwamoto T, Eagle RC. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology. 1984;91(11):1411-9.
15. Heufelder AE. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol. 1995;132(5):532-41.
16. Scott CD, Martin JL, Baxter RC. Rat hepatocyte insulin-like growth factor I and binding protein: effect of growth hormone in vitro and in vivo. Endocrinology. 1985;116(3):1102-7.
17. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993; 16(4):251-7.
18. Imai Y, Odajima R, Inoue Y, Shishiba Y. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh). 1992;126(6):541-52.
19. Cuevas E, Giménez-Gallego G, Carceller F, Cuevas B, Crespo A. Single topical application of human recombinant basic fibroblast growth factor (rbFGF) promotes neovascularization in rat cerebral cortex. Surg Neurol. 1993;39(5):380-4.
20. Gärtner R, Veitenhansl M, Aktas J, Schopohl D. Role of basic fibroblast growth factor in the pathogenesis of nodular goiter. Exp Clin Endocrinol Diabetes. 1996;104(Suppl 4):36-8.
21. Kodama M, Daa T, Kashima K, Yokoyama S, Nakayama I, Noguchi S. Immunohistochemical localization of acidic and basic fibroblast growth factors in human benign and malignant thyroid lesions. Jpn J Clin Oncol. 1994;24(2):66-73.
22. Duh QY, Siperstein AE, Miller RA, Sancho JJ, Demeure MJ, Clark OH. Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues. World J Surg. 1990;14(3):410-7; discussion 418.
23. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931-4.
24. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-5.
25. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178-87.
26. Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1998;83(11):3908-12.
27. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk- 1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene. 1997;15(22):2687-98.
28. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997; 82(11):3741-7.
29. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest. 1993;91(5):2235-43.
30. Berse B, Brown LF, Van Dde Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992; 3(2):211-20.